Why did the FDA refuse Moderna’s mRNA flu shot?
FDA halts review over trial and comparator concerns
U.S. regulators declined to accept Moderna’s application to license an mRNA‑based influenza vaccine, a move that surprised the company and reverberated across the vaccine industry. The agency said the submission failed to include evidence from an ‘‘adequate and well‑controlled’’ trial using an appropriate comparator; at the heart of the dispute is what standard of care Moderna used in its clinical study and whether that comparator allowed a reliable assessment of the new vaccine’s benefit.
The decision also reflected internal agency dynamics: senior officials overruled some reviewers who had been prepared to accept the application for review. Moderna has requested meetings with the agency to seek clarity and to discuss next steps.
Why the choice of comparator matters
- Scientific standard: regulators evaluate new vaccines by comparing them against the best available existing vaccine to show added or comparable protection.
- Trial design affects interpretability: if the comparator is not the accepted standard, results may not demonstrate meaningful benefit.
What this means going forward
- Moderna may need to run additional or redesigned trials that use the comparator the FDA considers appropriate, delaying potential approval.
- Other companies watching this precedent may face higher evidentiary expectations for novel flu vaccines, which could slow introductions of new platforms.
- The decision raises policy questions about regulatory consistency and industry incentives for investing in next‑generation vaccines.
Immediate practical effects are limited for the current flu season, because private and public programs rely on already‑approved influenza vaccines. Still, the refusal signals that regulators will scrutinise study design closely for mRNA and other innovative vaccine technologies; manufacturers and public‑health officials now await clearer guidance on acceptable trial frameworks.